
==== Front
Molecules
Molecules
molecules
Molecules
1420-3049
MDPI

10.3390/molecules26092668
molecules-26-02668
Review
Cancer Initiation, Progression and Resistance: Are Phytocannabinoids from Cannabis sativa L. Promising Compounds?
https://orcid.org/0000-0001-5637-1685
Nigro Ersilia 12
https://orcid.org/0000-0002-2567-2298
Formato Marialuisa 1
Crescente Giuseppina 1
https://orcid.org/0000-0002-9085-9737
Daniele Aurora 12*
Botta Bruno Academic Editor
BusardÃ² Francesco Paolo Academic Editor
1 Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche, UniversitÃ  della Campania â€œLuigi Vanvitelliâ€, Via G. Vivaldi 42, 81100 Caserta, Italy; nigro@ceinge.unina.it (E.N.); marialuisa.formato@unicampania.it (M.F.); giuseppina.crescente@unicampania.it (G.C.)
2 CEINGE-Biotecnologie Avanzate, Via G. Salvatore 486, 80145 Napoli, Italy
* Correspondence: aurora.daniele@unicampania.it
02 5 2021
5 2021
26 9 266814 3 2021
30 4 2021
Â© 2021 by the authors.
2021
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Cannabis sativa L. is a source of over 150 active compounds known as phytocannabinoids that are receiving renewed interest due to their diverse pharmacologic activities. Indeed, phytocannabinoids mimic the endogenous bioactive endocannabinoids effects through activation of CB1 and CB2 receptors widely described in the central nervous system and peripheral tissues. All phytocannabinoids have been studied for their protective actions towards different biological mechanisms, including inflammation, immune response, oxidative stress that, altogether, result in an inhibitory activity against the carcinogenesis. The role of the endocannabinoid system is not yet completely clear in cancer, but several studies indicate that cannabinoid receptors and endogenous ligands are overexpressed in different tumor tissues. Recently, in vitro and in vivo evidence support the effectiveness of phytocannabinoids against various cancer types, in terms of proliferation, metastasis, and angiogenesis, actions partially due to their ability to regulate signaling pathways critical for cell growth and survival. The aim of this review was to report the current knowledge about the action of phytocannabinoids from Cannabis sativa L. against cancer initiation and progression with a specific regard to brain, breast, colorectal, and lung cancer as well as their possible use in the therapies. We will also report the known molecular mechanisms responsible for such positive effects. Finally, we will describe the actual therapeutic options for Cannabis sativa L. and the ongoing clinical trials.

Cannabis sativa L.
phytocannabinoids
inflammation
cancer therapeutic agents
==== Body
1. Introduction

Cannabis sativa L. (Hemp) is a plant long used for its textile fibers and seed oil. Beyond these uses, it is the main source of over 150 active compounds known as phytocannabinoids [1] which have received renewed interest in recent years due to the diverse pharmacologic activities such as anti-inflammatory effects, cell growth inhibition, and tumor regression. Among the others and although not properly constitutive in hemp, the most representative compounds are Î”9-tetrahydrocannabinol (THC) and cannabidiol (CBD). The former, THC appears the most active [2,3] although its use is limited by the psychotropic effects it exerts, whereas CBD is the most abundant neutral form among phytocannabinoids in hemp. Compared to THC, CBD has non-psychoactive effects, an advantage for clinical applications. CBD has become extraordinarily popular around the world, being commercially available as dietary supplements, creams, lotions, and the most commonly used oils [4,5]. Furthermore, acidic cannabinoids such as cannabidiolic acid (CBDA) and tetrahydrocannabinol acid (THCA), together with cannabigerolic acid, are the main phytocannabinoids in hemp [6,7]; they lack psychoactive effects, and undergo decarboxylation by heat or aging. Another phytocannabinoid, less expressed in Cannabis sativa L., is cannabinol (CBN) which is a degradation product of the Cannabis metabolite Î”9-tetrahydrocannabinol, with a concentration in cannabis between 0.1 and 1.6% [8]. It is quite important to notice that a synergistic interaction of cannabinoids with terpenes and flavonoids has been proven. Indeed, terpenes are known to modulate THC pharmacokinetics by increasing bloodâ€“brain barrier (BBB) permeability [9]. Ratios between terpenoids and phytocannabinoids may substantially improve potential medical therapies [10]. Secondary metabolites may affect THC affinity for the CB1 receptor; flavonoids may also potentially affect THC pharmacokinetics [11].

Phytocannabinoids exert their biological effects by mimicking the actions of a family of endogenous bioactive mediators named endocannabinoids that activate two specific G proteinâ€“coupled cannabinoid receptors: CB1 and CB2 [12,13]. Both expression and function of CB1 have been widely described in the central and peripheral nervous system but their expression is present also in other peripheral tissues [14,15]. CB1 is a Gi/o type of GPCR that inhibits adenylyl cyclase (AC) activity and chunks the pathway of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Furthermore, CB1 suppresses the influx of Ca2+ ions and activates several components of the mitogen-activated protein kinases (MAPK) family and phosphoinositide-3-kinase/protein kinase B (PI3K/AKT) pathway [14,16]. CB2 is a GPCR-associated receptor, expressed as two isoforms, A and B. The isoform CB2A is mainly found in the testis and lower brain regions, while CB2B is more present in tissues of the immune system [13]. In addition, THC is a partial agonist of CB1 and CB2 receptors while CBD has greater affinity for CB2 than CB1 [17,18].

Nowadays, cannabinoids are being investigated as potential therapeutic agents for different pathologies [19], including cancer [20]. Indeed, both receptors, CB1 as well as CB2, are expressed in several cancer types including lung, breast and prostate cancer, glioblastoma, and colorectal cancer, further demonstrating an implication of the endocannabinoids system in cancer [16,21,22,23]. Furthermore, although CBN, CBG, and THCA effects have been less explored so far, all phytocannabinoids show protective effects towards a number of biological mechanisms, including inflammation, immune response, and oxidative stress. Altogether these effects result in an inhibitory activity against cancer [20]; on the other hand, emerging evidence demonstrated that phytocannabinoids can also modulate tumor growth through regulation of biological responses strictly related to the carcinogenesis process, such as inflammation, oxidative stress, and apoptosis [24].

In this scenario, the aim of this review was to report the current knowledge about the action of phytocannabinoids in Cannabis sativa L. against cancer initiation and progression with a specific regard to brain, breast, colorectal, and lung cancer, as well as their possible use in the therapies, substantially reducing the adverse effects. Furthermore, we reported the known molecular mechanisms responsible for such beneficial effects. Finally, we described the actual therapeutic options for Cannabis sativa L.

2. The Chemistry of Hemp

The phytochemistry of industrial Cannabis sativa L. is very complex with more than 500 secondary metabolites isolated and identified, of which a considerable number belongs to the phytocannabinoid class [25]. Phytocannabinoids are terpenophenolic compounds, whose carbon structure is mainly constituted by 22 or 21 carbon atoms, likely an alkyl resorcinol linking a monoterpene moiety (Figure 1). The polyketide pathway leads to an alkylresorcinol following the reaction between hexanoyl-CoA with three molecules of malonyl-CoA to yield olivetolic acid (OA). This latter undergoes prenylation by geranyl diphosphate (GPP), that derive from the deoxyxylulose phosphate/methylerythritol phosphate (DOXP/MEP) pathway [26]. Thus, through the cannabigerolic acid synthase (CBGAS) enzyme, mainly expressed in the glandular trichomes of female flowers, cannabigerolic acid (CBGA) is biosynthetized; this last is considered the precursor of all the phytocannabinoids [6,26]. Subsequently, CBGA is converted into CBDA, CBCA, and Î”9-THCA, through the action of flavinylated oxidases, namely cannabidiolic acid synthase (CBDAS), cannabichromenic acid synthase (CBCAS), and Î”9-tetrahydrocannabinolic acid synthase (Î”9-THCAS) [27]. Indeed, the versatility of phytocannabinoid biosynthesis augments the compoundsâ€™ structure variability, which further is affected by UV-light and temperature. Thus, phytocannabinoids differ into ten different main types (e.g., CBD-, Î”9/Î”8-THC-, CBG-, CBN-, CBND, CBT-, CBL-, CBE-, or CBC-type (Figure 2). A â€œmiscellaneousâ€ type is also reported, to which some different molecules, not chemically complying with the most common phytocannabinoids, such as cannabifuran (CBF-C5), dehydrocannabifuran (DCBF-C5), cannabicoumaronone-C5 (CBCON-C5).

Acetyl-CoA and butanoyl-CoA also react with malonyl-CoA derived-polyketide to produce other cannabinoid derivatives. In this context, a well-known example is cannabidivarinic acid, which could be considered a CBDA propyl analogue [7]. Moreover, acidic phytocannabinoids could undergo nonenzymatic decarboxylation to yield the neutral forms, which often retain or enhance the bioactivity of their precursors.

Beyond phytocannabinoids, Cannabis sativa L. is a source of a plethora of other compounds with pharmacological potential [28] such as terpenoids, alkaloids, and polyphenols (e.g., flavonoids, stilbenes, phenylpropanoid amides, lignanamides) [29]. In hemp, different flavonoids, that have been identified from pollen, leaves, and flowers, have as aglycone quercetin, kaempferol, orientin, apigenin, and luteolin [30]; these flavonoids could be present as C- or O-glycoside conjugates. Methylated prenylated flavones, cannflavins A, B, and C, as well as flavonols glycosides, such as kaempferol 3-O-sophoroside and quercetin 3-O-sophoroside, were also isolated from hemp pollen [31]. Furthermore, from Cannabis sativa L. fruits, beyond to a source to produce an oil rich in tocopherols and mono-, di-, and polyunsaturated fatty acids (PUFA) such as Î±-linolenic (ALA), Î³-linolenic acid (GLA), and stearidonic acid (SDA), contained different phenylamides, tyramine and octopamine derivatives of hydroxycinnamic acids, and their lignanamides, also called cannabisins [32,33].

3. A Brief Focus on Endocannabinoid System

The endocannabinoid system (ES) plays a key role in the inflammatory processes, and includes CB1 and CB2 cannabinoid receptors. The first endogenous cannabinoid ligands (eCBs), intensively investigated, are arachidonoylethanolamine (anandamide or AEA) and 2-arachidonoylglycerol (2-AG) [21]. Furthermore, ES comprises different enzymes involved in the synthesis, reuptake, and degradation of cannabinoids. Anandamide is synthesized from N-acyl-phosphatidylethanolamine (NAPE) by the enzyme NAPE-specific phospholipase D (NAPE-PLD), while 2-AG is synthesized from diacylglycerol (DAG) by DAG lipase (DAGL). The endocannabinoid system could be a target for different pathologies, in particular for cancer, with different levels of dysregulation that can involve cannabinoid receptors or the enzymes [34]. The most important enzyme involved in eCBs degradation are fatty acid amide hydrolase (FAAH) for anandamide and monoacylglycerol lipase (MAGL) for 2-arachidonoylglycerol. Beyond CB1 and CB2 cannabinoid receptors, other targets are suggested, such as GPR55 [35], transient receptor potential vanilloid 1 (TRPV1) ion channel [36], and peroxisome proliferator-activated receptor (PPAR) Î± and Î³ localized in the nucleus [37]. The CB1 and CB2 receptors are coupled to G protein, whose activation leads to an inhibition of adenyl cyclase, decreased production of cAMP, and variation of ion channel activity. THC is the most abundant cannabinoid and the first psychoactive constituent that was isolated in 1964 [38], which binds CB1 and CB2 receptors. THC, with its metabolite THC 11-oic, could explain analgesic, antiemetic, and antiglaucoma effects or anesthetic action [39]. Unlike THC, CBD acts as an antagonist of CB1 and CB2 receptors and its activity on the endocannabinoid system could be explained by its inhibition of FAAH enzyme for increase of endocannabinoids, such as anandamide, that normally have a short shell life. Beyond the action on the endocannabinoid system, there are different targets of CBD such as 5-HT1A, TRPV1A, D2, A1, MOR, PPAR Î³, sodium, and calcium channels [40]. These different endogenous targets underline the CBD actions on anxiety, depression, pain, memory, and metabolism (Figure 3). The activation of CB1/2 receptors and transient receptor potential (TRP), maybe vanilloid 1, could inhibit some cancer cell invasion and metastasis, acting on different pathways involved in the angiogenesis, tumor vascularization, and tumor cells ability to destroy matrix membranes. Nuclear receptors PPAR, in particular PPARÎ± and PPARÎ³, and the receptor GPR55 can be considered targets of cannabinoids also in cancer. Moreover, cyclooxygenase 2 (COX-2) can play a critical role on the behavior of endocannabinoids on cancer [41].

4. Molecular Effects of Cannabis sativa L.

Several molecular processes are strictly related to cancer initiation and development including inflammation, oxidative stress, and proliferation. Cannabinoids exert a number of beneficial pharmacological effects, including anti-inflammatory and antioxidant properties [42].

Several studies indicate that cannabinoid receptors and endogenous ligands are overexpressed in tumor tissues [43]. Moreover, increased expression of enzymes involved in endocannabinoid metabolism is often associated with the aggressiveness of cancer. [44,45]. Cannabinoids target the tumor affecting signaling and cellular pathways such as tumor cell proliferation, angiogenesis, tumor invasion, and apoptosis both in in vitro and in vivo experiments [46]. In particular, different evidence suggests that these compounds exert inhibition of initiation, progression, and metastatic capacity of several cancer types [17,43,47,48].

Both THC and non-psychoactive cannabinoids have been reported to possess peripheral anti-inflammatory properties in a plethora of in vitro and in vivo models [49,50,51]. In human peripheral blood cells, CB1 is expressed by B cells, NK cells, neutrophils, CD8+ T cells, monocytes, and CD4+ T cells, whereas CB2 mRNA is expressed by human B cells, NK cells, monocytes, neutrophils, and T cells [52]. Typically, CB2 inhibits the production of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-ð›¼), interleukin (IL)-2, IL-6, IL-8, and IFN-ð›¾ by immune cells [51]. CBD decreases peripheral inflammation through reduction of prostaglandin E2 (PGE2), nitric oxide (NO), and malondialdehyde production [53,54,55,56,57]. In addition, CBD, in combination with minor phytocannabinoids of Cannabis sativa L. extracts, can induce a greater pharmacological anti-inflammatory activity [52,58]. Indeed, a standardized cannabis extract enriched with CBD exerts a more powerful anti-inflammatory activity than CBD alone [59]. Besides CBD, THC also possesses potent anti-inflammatory properties both in vivo and in vitro [60,61]. Recently, in a mouse model of acute respiratory distress syndrome, THC leads to the suppression of the cytokine storm [62]. The molecular mechanisms at the basis of THC down-regulation of the inflammatory processes are various and tissue-dependent [61]. Indeed, regarding gastrointestinal and systemic inflammatory reactions, THC suppresses both lymphocytes and neutrophils activity [63,64]; in epithelial and skin cells, THC inhibits the release of inflammatory mediators through impairment of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway [65]. It is of note that there is clear evidence of the synergistic action of THC and CBD in terms of down-regulation of the inflammatory processes [66,67].

Regarding other combination extracts, Shebabya et al. demonstrated that Cannabis sativa L. oil extract markedly suppresses the release of TNF-Î± in LPS-stimulated rat monocytes with inhibition of LPS-induced COX-2 and i-NOS protein expression and blockage of MAPKs phosphorylation [68]. Additionally, the presence of phenols, terpenes, or other phytocannabinoids enhance the therapeutic activity of CBD, defined as â€˜entourage effectsâ€™ [69,70,71]. In addition, cannabis extract inhibits the production of IL-8, matrix metallopeptidase (MMP)-9, and vascular endothelial growth factor (VEGF), an effect not detected with CBD alone, in skin cells [65]. Other non-psychoactive cannabinoids, including CBC and CBN, also showed substantial in vivo anti-inflammatory responses. On the other hand, monoterpenes such as Î±- and Î²-pinene, myrcene, and limonene have been also reported to possess substantial anti-inflammatory properties [72,73,74].

Regarding neuroinflammation, both CBD and THC have protective effects [75,76,77] through the activation of NF-ðœ…B as well as the inhibition of Toll like receptor (TLR4) [78,79]. Indeed, in a vitro model of LPS-stimulated neuroinflammation, CBD suppresses the release of TNF-Î±, IL-1Î², and IL-6 through the inhibition of NF-ðœ…B phosphorylation and the concomitant activation of COX and iNOS [57,80]. In addition, THC treatment selectively reduces CD8+ T cell response accompanied by inhibition of IL-6 release [81]. The combination of THC and CBD seems to be the most potent anti-inflammatory drug able to inhibit the T helper response as well as CD4+ T response in a mouse model of multiple sclerosis (MS) [82].

Beyond the regulation of inflammation, phytocannabinoids can prevent proliferation, metastasis, and angiogenesis, as well as induce apoptosis in a variety of cancer cell types [83,84,85]. Treatments with CBC and THC or CBD led to cell cycle arrest and cell apoptosis. Additionally, CBC and THC or CBD treatments inhibit bladder urothelial carcinoma cell migration and affected F-actin integrity [86].

Beyond the actions of CBC, THC, and CBD on different pathways involved into development of cancer cell types, also cannabigerol (CBG), cannabidivarin (CBDV), cannabinol (CBN), cannabivarin (CBV), and tetrahydrocannabivarin (THCV) have showed a role as anti-cancer for different cells line [34].

Besides the anticancer effects, a role in the resistance to chemotherapy has also been suggested for Cannabis sativa L. [87]. P-gp is exclusively over expressed in cancer cells leading to multidrug resistance (MDR) [88]. Phytocompounds of Cannabis sativa L. can influence Pgp activity. Indeed, in multidrug resistant mouse lymphoma cells, cannabinol, cannabispirol, and cannabidiol increase cytotoxic drug accumulation [89]. Furthermore, Kazemi et al. showed that the lignanamides cannabisin M and cannabisin N have high binding affinities to Pgp, suggesting an inhibitory effect toward MDR [90].

From a molecular point of view, phytocannabinoids mainly stimulate molecular targets deeply involved in tumor development and progression such as the G-protein coupled receptors, peroxisome proliferator-activated receptors (PPARs), glycine receptors (GlyR), and transient receptor potential channels (TRP) channels [36].

In the next paragraphs, we will deepen the current knowledge about the in vitro effects of phytocannabinoids on different cancer cells with a particular regard to CBD and THC and the molecular mechanisms that underlie the inhibitory actions.

4.1. Brain Cancer

Both CBD and THC are promising compounds in the fight against brain cancers. Deng et al. showed that CBD induces a dose-dependent reduction of both proliferation and viability on glioblastoma multiform (GBM) cancer cells, with a IC50 ranging between 3.1 and 8.5 ÂµM. In addition, co-treatment of CBD with DNA damaging agents produces synergistic anti-proliferating and cell-killing responses in GMB cell line [91]. These data have been confirmed in the U-87 glioblastoma cell line in which CBD led to a concentration-related inhibition of the U87 cell viability [92]. In accordance, Nigro et al. analyzed, in the same glioblastoma cell line, the effects of a heterogenous extract from Cannabis Sativa L., finding the inhibition of both proliferation and migration from a dose of 25 Âµg/mL [32]. The underlying molecular mechanism is not completely clear but the authors evidenced DNA damage [32]. Recently, Singer et al. demonstrated that apoptosis together with ROS production are two additional mechanisms involved in CBD inhibitory activity of 3832 and 387 glioma primary stem cell lines (GSC) with an IC50 value of 3.5 Î¼M [93]. The induction of apoptosis has also been confirmed by Alharris et al. in neuroblastoma SH-SY5Y and IMR-32 cell lines in which a reduction of cancer cell migration and invasion was also induced already with a dose of 10 Î¼M [94]. A recent study suggested a role for CBD in interfering with chemoresistance in glioblastoma cells describing a decrease in prohibitin (PHB) and extracellular vescicles (EVs). EVs are lipid bilayer-enclosed structures which participate in cell-to-cell communication, both in physiological and pathophysiological processes regulating cell migration, differentiation, and angiogenesis and therefore playing an important role in cancers. Kosgodage et al. show that CBD reduces PHB protein levels and changes EV-mediated export of microRNAs to an anti-oncogenic signature in GBM cells [95].

Interestingly, it is to notice that cannabinoid treatment cannot affect cell viability of astrocytes (normal glial cells) in comparison to GBM cells, demonstrating a selectivity towards cancer cells. However, the molecular mechanisms mediating cannabinoid selectivity are not yet fully understood [96,97].

Regarding THC, similar anti-cancer effects have been demonstrated: BlÃ¡zquez et al. found that, in mice and glioma cells, THC inhibits the growth and invasion of gliomas through the down-regulation of matrix metalloproteinase (MMP-2 expression), factor involved in the acquisition of invasiveness [98]. The anti-cancer activity of THC on recurrent GBM has also been demonstrated in vivo [99]. The mechanism underlying the THC anticancer properties has been only partially clarified and relies on the stimulation of an ER stress-related signaling pathways that unleash the autophagy-mediated cancer cell death [20,100]. Whether CBD or THC are more potent in antineoplastic activity on brain cells is still a matter of debate. Marcu et al. conducted experiments comparing the two molecules, concluding that CBD is a more potent inhibitor than THC in different glioblastoma cell lines (U87-MG, U251, and SF126) [101].

Besides the use of single cannabinoid, Baram et al. described cannabis extracts as antitumor agents in U-87 MG and T98G glioblastoma cell lines able to impair the survival and proliferation of cancer cells as well as induced apoptosis, to a greater extent than THC alone [102]. In addition, in a combination study, Valero et al. reported that a CBD concentration higher than THC (5:1), in combination with temozolomide [CBD (15 mg/kg) and TMZ (5 mg/kg)], targeted glioma stem cells in vivo much more efficiently than the THC/CBD formulation [103]. Remaining on the evaluation of combinational treatments, Ivanov et al. demonstrated the upregulation of the cytotoxic effect of Î³-irradiation in GBM by the co-treatment with CBD. The dose of CBD treatment ranged between 5 and 20 ÂµM, in accordance with previous results. The authors also found that CBD treatment substantially upregulated TNF/TNFR1 and TRAIL/TRAIL-R2 signaling by modulation of both ligand and receptor levels followed by apoptosis. The pathways triggered by CBD are JNK1/2 and MAPK p38 levels with the subsequent downregulation of the active phospho-ERK1/2 and phospho-AKT levels [104,105]. On the contrary, in a different cellular model, the U251 cell line, Marcu et al. showed that CBD did not increase the activity of JNK1/2 or p38 MAPK [101].

In addition to irradiation, CBD has also been tested with alkylating agents, especially TMZ, proving that together they have synergistic anti-proliferative effects on glioma cells [52,60,61,65].

Beyond proliferation and apoptosis, several papers reported in the GBM cell line an induction of oxidative stress by CBD treatment, accompanied by a decrease of the antioxidant cell potential, [106,107]. Interestingly, there is no ROS increase in CBD treated normal glial cells [107].

4.2. Lung Cancer

Cannabinoids and their agonists have been proposed as complementary pharmacological agents in the treatment of lung cancer thanks to their antineoplastic, apoptotic, and anti-metastatic properties [43]. A recent work by Milian et al., showed that lung tumors can be classified according to the expression of CB1 and CB2 receptors because patients with high expression levels of both receptors are associated with a better prognosis of the disease and survival [108].

In vitro studies have largely evidenced that both CBD and THC inhibit viability as well as invasiveness of lung cancer cells [109,110]. Ramer et al. demonstrated that CBD caused a profound inhibition of viability and invasion capacity of A549 and H460 lung cancer cells, accompanied by a decreased expression and secretion of PAI-1, at very low concentrations (as low as 0.1 Î¼M); these events are CB1-, CB2-, and TRPV1-dependent. The authors also found that CBD reduces in vivo the size of tumor in nude mice [109].

Similar to CBD, THC has been found to suppresses viability and invasiveness of three different lung cancer cell lines (H1299, A549, H1975) deterring cell migration and abolishing cytoskeleton reorganization/focal adhesion assembly at a dose of 10 Î¼M [111]. The molecular mechanism of action of THC passed through the abolishment of Src-dependent cytoskeleton reorganization and focal adhesion assembly diminished, both processes deeply involved in carcinogenesis and metastasis [24].

Recently, Cannabis Sativa female flower heterogenous extracts have been found to induce death of lung cancer A549 cell line in a time-dependent manner but at very low doses (50â€“900â€‰ng/mL), following induction of early apoptosis, cell cycle arrest, elevation of ROS level, and activation of caspase 3 [112]. The mechanism seems to be mediated by the binding to the CB2 receptors, since their blockage caused attenuation of Cannabis Sativa effects on A549 cells [112].

Similar to what was described in brain cancer cells, besides the use of single cannabinoids, Baram et al. described cannabis extracts as antitumor agents in A549 and NCI-H460 lung carcinoma to a greater extent than THC alone [102]. The underlying molecular mechanisms and signaling pathways are mainly related to the activation of the extracellular signal-related kinase (ERK), phosphoinositide3-kinase (PI3K), p38mitogen-activated protein kinase (p38MAPK), and ceramide pathways [113]. Another mechanism demonstrated in CBD-treated lung cancer is the up-regulation of cyclooxygenase-2 (COX-2) and PPAR-gamma in vitro as well as in vivo [110]. Regarding the anti-metastatic activity, two mechanisms, directly correlated with the invasion process, have been proposed to be induced by cannabinoids: a) decreased secretion of plasminogen activator inhibitor-1 (PAI-1) [109]; b) an upregulation in the expression of ICAM-1 [114].

4.3. Breast Cancer

In preclinical studies, CB1 and CB2 agonists (CBD, THC, and synthetic) have been shown to inhibit the proliferation of estrogen receptors positive breast cancer cell lines [14]. Accordingly, a cytotoxic effect of CBD was observed in several cell lines including estrogen-receptor (ER)-positive cells (MCF-7, ZR-75-1, T47D), ER-negative cells (MDA-MB-231, MDA-MB-468, and SK-BR3), and triple-negative breast cancer cells (SUM159, 4T1up, MVT-1, and SCP2) [115,116,117,118,119].

In particular, CBD induces apoptosis and reticulum stress in MDA-MB-231 and MCF7 cancer cells inhibiting their growth [119]. Other studies confirmed these data in several breast cancer cell lines, showing inhibition of cell growth, DNA fragmentation, and apoptosis [120,121]. In addition, CBD treatment induces an enhancement in the level of ROS in breast cancer cells [70]. Furthermore, CBD induces apoptosis and blocks cell viability through the inhibition of the AKT/mTOR axis and cyclin D together with the enhancement of ROS generation [115,116]. Similarly, THC showed anti-proliferative effects on several breast cancer cell lines [116,122]. Elbaz et al. observed that CBD specifically inhibits the epidermal growth factor-induced proliferation, suggesting it as a novel potential therapeutic option for breast cancer [115].

Interestingly, CBD has been associated to sensitivity to chemotherapy; in MDA-MB-231 cells, it significantly reduces exosome release and inhibits microvesicle release [123] at a concentration of 1 and 5 Î¼M. These regulatory processes may be associated with changes in mitochondrial function, including modulation of STAT3 and prohibitin expression, candidating CBD as a molecule useful to sensitize breast cancer cells to chemotherapy.

Besides natural compounds, synthetic agonists for cannabinoid receptors (WIN55, 212-2, and JWH-133) have also been tested in breast cancer showing dose-dependent anti-proliferative and anti-migration effects [123,124,125,126]. Comparably to natural ones, the effects induced by the agonists might be linked to the induction of autophagy and inhibition of cell-cycle progression through the enhancement of ROS production [119,126].

Regarding the minor phytocannabinoids, in MDA-MB-231 breast carcinoma cells, both CBG and CBC were shown to inhibit cell growth, inhibiting the uptake of [14C]anandamide and activating the vanilloid receptor TRPV1 [70]. Similarly, CBN has some antiproliferative effects in aggressive breast cancer cells [118], while CBC powerfully inhibits cell viability in both MDA-MB-231 and MCF-7 breast cancer cell lines, [70] and CBN has been revealed to have antiproliferative effects in aggressive breast cancer cells [127]. Among other terpenes, pinene shows anti-proliferative effects against MCF-7 breast cancer cells [34,128]. Several studies showed that limonene has anticancer effects on mammary carcinoma models causing regression and inhibiting subsequent tumor formation [129,130,131].

4.4. Colorectal Cancer

Normal and cancerous human colorectal tissues express both CB1 and CB2, indicating that cannabinoids have biological effects not only on colon but also on colorectal cancer. In this context, Aviello et al. showed that CBD exerts significant antiproliferative effects in Caco-2 and HCT116 colorectal carcinoma cell lines through induction of caspase 3 and apoptosis with an IC50 value reported as 7.5 Â± 1.3 Î¼M [132]. The molecular mechanisms underlying such effects are related to multiple pathways, such as mediated by CB(1)-, TRPV1, and PPARÎ³-antagonists sensitive manner [132]. Accordingly, Ligresti et al. reported that cannabinoid treatments decreased cell viability in undifferentiated Caco-2 cells via CB1 receptor. In comparison to the undifferentiated cells, CaCo-2 differentiated cells did not respond to cannabinoid treatments. It is interesting to note that the overall CB1 expression levels remained unchanged after differentiation [53,70,133].

In line with this study, it was demonstrated that HCT116 and DLD-1 colorectal cancer cells, treated with different concentrations of CBD, present elevated rate of apoptosis at treatment doses as low as 4 Î¼M [134]; the selectivity of CBD actions have also been proved since no effects have been found in normal primary colorectal CCD-18Co cells and normal primary lung Beas2B cells. Regarding the mechanisms of death triggered by CBD, it has been shown that it induces Noxa-mediated apoptosis through the generation of ROS and excessive ER stress in both HCT116 and DLD-1 cells [134]. Jeong et al. also found that Noxa-activated apoptosis was dependent on excessive ER stress from ATF3 and ATF4 [134]. An additional pathway that, at least in part, contributes to CBD effects, is linked to autophagy-mediated death as well as to the arrest of cell cycle [126]. Kis et al. investigated the effects of CBD on the CT26 colon cancer cell line, showing that the beneficial effects of CBD are due to relevant antioxidant activity mediated by superoxide dismutase (SOD) and glutathione peroxidase (GPX) [1].

The possible use of phytocannabinoids in combination with different conventional therapies is gaining increased attention. Although oxaliplatin is an effective chemotherapeutic drug CRC treatment, patients often develop resistance to it; NOS3 is an essential molecular target for oxaliplatin resistance. The combinational treatment in vitro of CRC cells with oxaliplatin and CBD is able to decrease NOS3 phosphorylation, resulting in autophagy, and overproduction of ROS, thus overcoming oxaliplatin resistance [135].

It is relevant to notice that, both THC and CBD are able to restore the increase of the permeability and inflammation of intestinal cells, events typically occurring during the neoplastic process [136,137]; these THC and CBD effects suggest the regulation of inflammation as an additional mechanism for the anticancer effects. In line with this hypothesis, cytokines levels are significantly reduced by CBD treatment in in vitro models of colorectal cancer [138,139].

Regarding minor phytocannabinoids, CBG also stimulates apoptosis, ROS production, up-regulates C/EBP homologous protein (CHOP) mRNA, and inhibits cell proliferation in colorectal cancer cells [140]. Similarly, in Caco-2 cells, CBC can inhibit cell growth, but only at a concentration of 30 ÂµM and CBDV reduces cell viability in a concentration-dependent manner, with an IC50 of 10 ÂµM [141].

Myrcene extracts show significant cytotoxic effects in various tumors including breast carcinoma and colon adenocarcinoma [142] and other cell lines [143,144]. Similarly, in colon cancer cells, D-limonene suppresses cell viability through the induction of apoptosis via the suppression of the PI3K/Akt pathway [145].

5. Cannabis sativa L. in Cancer Clinical Trials

The role of Cannabis sativa in medicine is rapidly evolving. More than 30 countries worldwide have now legalized access to medical use of Cannabis [146,147]. A prospective observational study showed that many cancer-related symptoms improve significantly with Cannabis consumption. Similarly, another study, performed on over 3000 cancer patients, showed that cannabis use determines significant improvements in the control of common symptoms, including sleep problems (70.8%), fatigue (55.9%), anxiety and depression (74.1%), and nausea and vomiting (54.7%) [148].

Compared to THC, CBD-based preparations seem to be more promising, having diverse medicinal properties, such as anti-nausea, anti-emetic, anti-tumor, anti-inflammatory, antidepressant, anti-psychotic, and anti-anxiolytic effects [149]. To date, some information has been collected also in relation to the anticancer effects of CBD [92,150], as well as for the management of cancer pain, cancer-related anorexia and cachexia, and chemotherapy-induced nausea and vomiting (CINV) [151,152,153].

Clinical data are available about CBD use for the treatment of glioblastoma. A clinical trial analyzed the effect of CBD as a single agent against glioblastoma (clinical trial: NCT02255292) while another placebo-controlled phase II clinical trial analyzed the effect of the combination of THC and CBD as adjuvant in the chemotherapy (clinical trial: NCT01812603) [https://clinicaltrials.gov/ct2/show accessed on 30 April 2021]. Both trials report very promising effects in terms of cancer regression.

Similarly, a clinical trial, regarding 119 patients with different solid tumors (e.g., breast, prostate, and esophageal), was conducted over a four-year framed period: in 92% of the patients, a reduction in tumor size was obtained when CBD oil was administered [154].

Besides trials aiming at validating anti-cancer properties, the effects of CBD-based preparations on cancer pain patients are finding a wide interest [155,156,157,158,159]. A significant analgesic effect has been assessed in patients with malignant disease in 15 of 18 trials as compared to placebo [160]. Several data have demonstrated improved average pain score and an increased good quality of life [161,162,163]. Additionally, when using various THC dosages or synthetic analogs for cancer-related pain, an improved pain relief was found [164,165]. Even in cancer patients suffering from inadequate analgesia control with opioid therapy, a combination of THC and CBD can reduce pain score more than 30% from baseline [166,167], while the THC group showed a non-significant improvement [37]. However, the main limitation of THC remains sedation [168,169], while the long-term use of the THC/CBD spray is generally well-tolerated for as long as 2 years [170].

CB receptors, highly expressed in the neuronal tracts for emesis, have been chosen for treating CINV [171]. Results from several preclinical studies suggest that THC and CBD have anti-inflammatory, analgesic, anti-nausea, antiemetic, anti-psychotic, anti-ischemic, anxiolytic, and anti-epileptic impact [172,173,174]. In a small, controlled, randomized, â€œdouble-blindâ€ experiment, oral THC reduces vomiting caused by chemotherapeutic agents [175].

Finally, the use of cannabinoids is linked to the increase of appetite and the gain of weight (ClinicalTrials.gov accessed on 14 March 2021, NCT02359123) [151]. However, cannabis extract and THC were tested in a Phase III clinical trial with no significant differences among patients with cancer-related anorexia-cachexia syndrome in terms of appetite [152]. More promising results have been later obtained that described a relevant increase in appetite [176]. Finally, in cachectic NSCLC patients, the use of a synthetic analog of THC, in a Phase II trial, significantly increases appetite and caloric intake [23]. No significant differences between THC/CBD and THC alone have not been observed [152].

6. Conclusions

There is still urgent need of improving cancer treatment through the identification of a novel pharmacological drug. In this context, the phytocannabinoids from Cannabis sativa L. are receiving growing attention due to their promising therapeutic potential about the treatment of variety of cancers such as that affecting brain, breast, lung, and colon. Indeed, whether at present and undoubtedly, the cannabinoids are in use for the control of adverse reactions to conventional cancer treatments, an additional important direct role of these compounds in the development, progression, and metastasis of tumors is emerging. Furthermore, increasing the body of in vitro and in vivo evidence supports apoptosis, proliferation, and inflammation such as underlying mechanisms through which cannabinoids exert their anticancer effects (schematically reported in Figure 4). In addition, several evidence indicate that the activity of phytocannabinoids might be more effective in combinational therapies, encouraging to explore novel combinations and treatment schedules. However, the translation of cannabinoids use into clinical practice is still now in the initial phases.

Further studies will facilitate a better understanding of the effective application of cannabinoids in oncology.

Acknowledgments

The study was supported by: grant â€œProgramma VALERE 2019â€ from the University of Campania â€œLuigi Vanvitelliâ€ (Head-on project); POR CAMPANIA FESR 2014/2020. Project- â€œiCUREâ€ CUP: B21C17000030007.

Author Contributions

E.N. and A.D. convinced the study and reviewed the literature data regarding the biological effects of hemp. M.F. and G.C. reviewed the literature data regarding the chemistry of the hemp. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

THC	Î”9-tetrahydrocannabinol	
CBD	cannabidiol	
CBDA	cannabidiolic acid	
THCA	tetrahydrocannabinol acid	
CBN	cannabinol	
AC	adenylyl cyclase	
CB1 and CB2	cannabinoid receptor 1 and 2	
cAMP	adenosine monophosphate	
PKA	protein kinase A	
MAPK	protein kinases	
PI3K/AKT	phosphoinositide-3-kinase/protein kinase B	
BBB	bloodâ€“brain barrier	
OA	olivetolic acid	
CBGAS	cannabigerolic acid synthase	
CBGA	cannabigerolic acid	
CBDAS	cannabidiolic acid synthase	
Î”9-THCAS	Î”9-tetrahydrocannabinolic acid synthase	
CBF-C5	cannabifuran	
DCBF-C5	dehydrocannabifuran	
CBCON-C5	cannabicoumaronone-C5	
CBGVA	cannabigerovarinic acid	
PUFA	polyunsaturated fatty acids	
ALA	Î±-linolenic	
GLA	Î³-linolenic acid	
SDA	stearidonic acid	
ES	endocannabinoid system	
eCBs	endogenous cannabinoid ligands	
NAPE	N-acyl-phosphatidylethanolamine	
NAPE-PLD	NAPE-specific phospholipase D	
DAG	diacylglycerol	
DAGL	DAG lipase	
FAAH	fatty acid amide hydrolase	
MAGL	monoacylglycerol lipase	
TRPV1	transient receptor potential vanilloid 1	
PPAR	peroxisome proliferator-activated receptor	
TRP	transient receptor potential	
TNF-ð›¼	Tumor Necrosis Factor alpha	
IL	Interleukin	
NF-kB	nuclear factor kappa-light-chain-enhancer of activated B cells	
COX-2	Cyclooxygenase 2	
PGE2	Prostaglandin E2	
NO	nitric oxide	
TLR4	Toll like receptos 4	
MMP	matrix metallopeptidase	
VEGF	vascular endothelial growth factor	
MDR	multidrug resistance	
GBM	glioblastoma multiforme	
GSC	glioma stem cell lines	
ERK	extracellular signal-related kinase	
PI3K	phosphoinositide3-kinase	
p38MAPK	p38mitogen-activated protein kinase	
ER	estrogen receptors	
SOD	Superoxide dismutase	
GPX	glutathione peroxidase	
CINV	chemotherapy-induced nausea and vomiting	

Figure 1 (A) General overview of cannabinoidsâ€™ biosynthetic pathway; (B) Butanoyl-CoA is involved in the biosynthesis of propyl cannabinoids, of which cannabigerovarinic acid (CBGVA) is the precursor compound.

Figure 2 Cannabinoid type derived from an olivetoid backbone. R = H (neutral cannabinoids); R = COOH (acidic cannabinoids).

Figure 3 Multiple molecular targets for THC and CBD; agonist â†’; antagonist êŸ·êŸ¾; negative allosteric modulator ---âž; inhibitor ---êŸ¾; partial agonist --->.

Figure 4 Schematic representation of the multiple molecular effects of phytocannabinoids from Cannabis Sativa L. against brain, lung, breast and colorectal cancer.

Publisherâ€™s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Kis B. Ifrim F.C. Buda V. Avram S. Pavel I.Z. Antal D. Paunescu V. Dehelean C.A. Ardelean F. Diaconeasa Z. Cannabidiolâ€”from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer Int. J. Mol. Sci. 2019 20 5905 10.3390/ijms20235905 31775230
2. Diviant J.P. Vigil J.M. Stith S.S. The Role of Cannabis within an Emerging Perspective on Schizophrenia Medicines 2018 5 86 10.3390/medicines5030086 30096776
3. Micale V. Drago F. Endocannabinoid system, stress and HPA axis Eur. J. Pharmacol. 2018 834 230 239 10.1016/j.ejphar.2018.07.039 30036537
4. Farinon B. Molinari R. Costantini L. Merendino N. The seed of industrial hemp (Cannabis sativa L.): Nutritional Quality and Potential Functionality for Human Health and Nutrition Nutrients 2020 12 1935 10.3390/nu12071935 32610691
5. McPartland J.M. Duncan M. Di Marzo V. Pertwee R.G. Are cannabidiol and Î”9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review Br. J. Pharmacol. 2015 172 737 753 10.1111/bph.12944 25257544
6. Formato M. Crescente G. Scognamiglio M. Fiorentino A. Pecoraro M.T. Piccolella S. Catauro M. Pacifico S. (â€’)-Cannabidiolic Acid, a Still Overlooked Bioactive Compound: An Introductory Review and Preliminary Research Molecules 2020 25 2638 10.3390/molecules25112638
7. Piccolella S. Crescente G. Formato M. Pacifico S. A Cup of Hemp Coffee by Moka Pot from Southern Italy: An UHPLC-HRMS Investigation Foods 2020 9 1123 10.3390/foods9081123
8. Chousidis I. Chatzimitakos T. Leonardos D. Filiou M.D. Stalikas C.D. Leonardos I.D. Cannabinol in the spotlight: Toxicometabolomic study and behavioral analysis of zebrafish embryos exposed to the unknown cannabinoid Chemosphere 2020 252 126417 10.1016/j.chemosphere.2020.126417 32200177
9. Lewis M.A. Russo E.B. Smith K.M. Pharmacological Foundations of Cannabis Chemovars Planta Med. 2017 84 225 233 10.1055/s-0043-122240 29161743
10. Namdar D. Voet H. Ajjampura V. Nadarajan S. Mayzlish-Gati E. Mazuz M. Shalev N. Koltai H. Terpenoids and Phytocannabinoids Co-Produced in Cannabis Sativa Strains Show Specific Interaction for Cell Cytotoxic Activity Molecules 2019 24 3031 10.3390/molecules24173031
11. Santiago M. Sachdev S. Arnold J.C. McGregor I.S. Connor M. Absence of Entourage: Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Î”9-THC at Human CB1and CB2Receptors Cannabis Cannabinoid Res. 2019 4 165 176 10.1089/can.2019.0016 31559333
12. Howlett A.C. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors Pharmacol. Rev. 2002 54 161 202 10.1124/pr.54.2.161 12037135
13. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Î”9 -tetrahydrocannabinol, cannabidiol and Î”9 -tetrahydrocannabivarin Br. J. Pharmacol. 2008 153 199 215 10.1038/sj.bjp.0707442 17828291
14. DoboviÅ¡ek L. KrstanoviÄ‡ F. BorÅ¡tnar S. Debeljak N. Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment Cancers 2020 12 525 10.3390/cancers12030525 32106399
15. Mackie K. Distribution of Cannabinoid Receptors in the Central and Peripheral Nervous System Organotypic Models Drug Dev. 2005 168 299 325 10.1007/3-540-26573-2_10
16. Zou S. Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System Int. J. Mol. Sci. 2018 19 833 10.3390/ijms19030833
17. Pertwee R.G. Neuropharmacology and therapeutic potential of cannabinoids Addict. Biol. 2000 5 37 46 10.1080/13556210071252 20575818
18. Zettl U.K. Rommer P. Hipp P. Patejdl R. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis Ther. Adv. Neurol. Disord. 2015 9 9 30 10.1177/1756285615612659 26788128
19. Pertwee R.G. Cannabinoid pharmacology: The first 66 years Br. J. Pharmacol. 2009 147 S163 S171 10.1038/sj.bjp.0706406
20. Velasco G. HernÃ¡ndez-Tiedra S. DÃ¡vila D. Lorente M. The use of cannabinoids as anticancer agents Prog. Neuropsychopharmacol. Biol. Psychiatry 2016 64 259 266 10.1016/j.pnpbp.2015.05.010 26071989
21. Pertwee R.G. Endocannabinoids and their pharmacological actions Endocannabinoids Pertwee R.G. Springer Berlin/Heidelberg, Germany 2015 Volume 231 1 37 10.1007/978-3-319-20825-1_1
22. Liu Q.-R. Pan C.-H. Hishimoto A. Li C.-Y. Xi Z.-X. Llorente-Berzal A. Viveros M.-P. Ishiguro H. Arinami T. Onaivi E.S. Species differences in cannabinoid receptor 2 (CNR2gene): Identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands Genes Brain Behav. 2009 8 519 530 10.1111/j.1601-183X.2009.00498.x 19496827
23. Turcotte C. Blanchet M.-R. LaViolette M. Flamand N. The CB2 receptor and its role as a regulator of inflammation Cell. Mol. Life Sci. 2016 73 4449 4470 10.1007/s00018-016-2300-4 27402121
24. Afrin F. Chi M. Eamens A.L. Duchatel R.J. Douglas A.M. Schneider J. Gedye C. Woldu A.S. Dun M.D. Can Hemp Help? Low-THC Cannabis and Non-THC Cannabinoids for the Treatment of Cancer Cancers 2020 12 1033 10.3390/cancers12041033 32340151
25. ElSohly M.A. Radwan M.M. Gul W. Chandra S. Galal A. Phytochemistry of Cannabis sativa L. Prog. Chem. Org. Nat. Prod. 2017 103 1 36 10.1007/978-3-319-45541-9_1 28120229
26. Fellermeier M. Zenk M.H. Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol FEBS Lett. 1998 427 283 285 10.1016/S0014-5793(98)00450-5 9607329
27. Carvalho Ã‚. Hansen E.H. Kayser O. Carlsen S. Stehle F. Designing microorganisms for heterologous biosynthesis of cannabinoids FEMS Yeast Res. 2017 17 fox037 10.1093/femsyr/fox037
28. Russo E.B. Marcu J. Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads Adv. Pharmacol. 2017 80 67 134 10.1016/bs.apha.2017.03.004 28826544
29. Flores-Sanchez I.J. Verpoorte R. PKS Activities and Biosynthesis of Cannabinoids and Flavonoids in Cannabis sativa L. Plants Plant. Cell Physiol. 2008 49 1767 1782 10.1093/pcp/pcn150 18854334
30. Minassi A. Fresu L.G. Cannabis Phenolics and their Bioactivities Curr. Med. Chem. 2018 25 1160 1185 10.2174/0929867324666170810164636 28799497
31. Ross S.A. ElSohly M.A. Sultana G.N.N. Mehmedic Z. Hossain C.F. Chandra S. Flavonoid glycosides and cannabinoids from the pollen of Cannabis sativa L. Phytochem. Anal. 2005 16 45 48 10.1002/pca.809 15688956
32. Nigro E. Crescente G. Formato M. Pecoraro M.T. Mallardo M. Piccolella S. Daniele A. Pacifico S. Hempseed Lignanamides Rich-Fraction: Chemical Investigation and Cytotoxicity towards U-87 Glioblastoma Cells Molecules 2020 25 1049 10.3390/molecules25051049 32110947
33. Crescente G. Piccolella S. Esposito A. Scognamiglio M. Fiorentino A. Pacifico S. Chemical composition and nutraceutical properties of hempseed: An ancient food with actual functional value Phytochem. Rev. 2018 17 733 749 10.1007/s11101-018-9556-2
34. Tomko A.M. Whynot E.G. Ellis L.D. DuprÃ© D.J. Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis Cancers 2020 12 1985 10.3390/cancers12071985 32708138
35. Ross R.A. The enigmatic pharmacology of GPR55 Trends Pharmacol. Sci. 2009 30 156 163 10.1016/j.tips.2008.12.004 19233486
36. Marzo V. Petrocellis L. Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: A Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs Curr. Med. Chem. 2010 17 1430 1449 10.2174/092986710790980078 20166923
37. Pistis M. Melis M. From surface to nuclear receptors: The endocannabinoid family extends its assets Curr. Med. Chem. 2010 17 1450 1467 10.2174/092986710790980014 20166922
38. Gaoni Y. Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish J. Am. Chem. Soc. 1964 86 1646 1647 10.1021/ja01062a046
39. Nahas G. Harvey D.J. Sutin K. Turndorf H. Cancro R. A molecular basis of the therapeutic and psychoactive properties of cannabis (Î”9-tetrahydrocannabinol) Prog. Neuropsychopharmacol. Biol. Psychiatry 2002 26 721 730 10.1016/S0278-5846(01)00245-7 12188105
40. De Almeida D.L. Devi L.A. Diversity of molecular targets and signaling pathways for CBD Pharmacol. Res. Perspect. 2020 8 e00682 10.1002/prp2.682 33169541
41. Brown I. Cascio M.G. Rotondo D. Pertwee R.G. Heys S.D. Wahle K.W. Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators Prog. Lipid Res. 2013 52 80 109 10.1016/j.plipres.2012.10.001 23103355
42. Atalay S. Jarocka-Karpowicz I. Skrzydlewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol Antioxidants 2019 9 21 10.3390/antiox9010021 31881765
43. DariÅ¡ B. Verboten M.T. Knez Å½. Ferk P. Cannabinoids in cancer treatment: Therapeutic potential and legislation Bosn. J. Basic Med. Sci. 2019 19 14 23 10.17305/bjbms.2018.3532 30172249
44. Malfitano A.M. Ciaglia E. Gangemi G. Gazzerro P. Laezza C. Bifulco M. Update on the endocannabinoid system as an anticancer target Expert Opin. Ther. Targets 2011 15 297 308 10.1517/14728222.2011.553606 21244344
45. Sailler S. Schmitz K. JÃ¤ger E. Ferreiros N. Wicker S. Zschiebsch K. Pickert G. Geisslinger G. Walter C. Tegeder I. Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans Oncoscience 2014 1 272 282 10.18632/oncoscience.33 25594019
46. Velasco G. SÃ¡nchez C. GuzmÃ¡n M. Anticancer Mechanisms of Cannabinoids Curr. Oncol. 2016 23 23 32 10.3747/co.23.3080
47. Khan M.I. Soboci A.A. Szczylik C. Czarnecka A.M. KrÃ³l M. Botta B. The Therapeutic Aspects of the Endocannabinoid System (ECS) for Cancer and their Development: From Nature to Laboratory Curr. Pharm. Des. 2016 22 1756 1766 10.2174/1381612822666151211094901 26654588
48. ÅšledziÅ„ski P. Zeyland J. SÅ‚omski R. Nowak A. The current state and future perspectives of cannabinoids in cancer biology Cancer Med. 2018 7 765 775 10.1002/cam4.1312 29473338
49. Jamontt J. Molleman A. Pertwee R.G. Parsons M.E. The effects of Î”9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation andin vitromotility disturbances in rat colitis Br. J. Pharmacol. 2010 160 712 723 10.1111/j.1476-5381.2010.00791.x 20590574
50. Sido J.M. Jackson A.R. Nagarkatti P.S. Nagarkatti M. Marijuana-derived Î”-9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation J. Mol. Med. 2016 94 1039 1051 10.1007/s00109-016-1404-5 27038180
51. McCoy K.L. Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation Mediat. Inflamm. 2016 2016 1 18 10.1155/2016/5831315
52. Pellati F. Borgonetti V. Brighenti V. Biagi M. Benvenuti S. Corsi L. Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer BioMed Res. Int. 2018 2018 1 15 10.1155/2018/1691428 30627539
53. Ligresti A. De Petrocellis L. Di Marzo V. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology Physiol. Rev. 2016 96 1593 1659 10.1152/physrev.00002.2016 27630175
54. Costa B. Colleoni M. Conti S. Parolaro D. Franke C. Trovato A.E. Giagnoni G. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw Naunyn. Schmiedebergs. Arch. Pharmacol. 2004 369 294 299 10.1007/s00210-004-0871-3 14963641
55. Burstein S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation Bioorganic Med. Chem. 2015 23 1377 1385 10.1016/j.bmc.2015.01.059
56. De Filippis D. Esposito G. Cirillo C. Cipriano M. De Winter B.Y. Scuderi C. Sarnelli G. Cuomo R. Steardo L. De Man J.G. Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis PLoS ONE 2011 6 e28159 10.1371/journal.pone.0028159 22163000
57. Kozela E. Pietr M. Juknat A. Rimmerman N. Levy R. Vogel Z. Cannabinoids Î”9-Tetrahydrocannabinol and Cannabidiol Differentially Inhibit the Lipopolysaccharide-activated NF-ÎºB and Interferon-Î²/STAT Proinflammatory Pathways in BV-2 Microglial Cells J. Biol. Chem. 2010 285 1616 1626 10.1074/jbc.M109.069294 19910459
58. De Petrocellis L. Ligresti A. Moriello A.S. Iappelli M. Verde R. Stott C.G. Cristino L. Orlando P. Di Marzo V. Non-THC cannabinoids inhibit prostate carcinoma growthin vitroandin vivo: Pro-apoptotic effects and underlying mechanisms Br. J. Pharmacol. 2012 168 79 102 10.1111/j.1476-5381.2012.02027.x
59. Gallily R. Yekhtin Z. HanuÅ¡ L.O. Overcoming the bell-shaped dose-response of cannabidiol by using cannabis extract en-riched in cannabidiol Pharmacol. Pharm. 2015 6 75 10.4236/pp.2015.62010
60. Maselli D.B. Camilleri M. Pharmacology, Clinical Effects, and Therapeutic Potential of Cannabinoids for Gastrointestinal and Liver Diseases Clin. Gastroenterol. Hepatol. 2020 1542 10.1016/j.cgh.2020.04.020
61. Miller H.P. Bonawitz S.C. Ostrovsky O. The effects of delta-9-tetrahydrocannabinol (THC) on inflammation: A review Cell. Immunol. 2020 352 104111 10.1016/j.cellimm.2020.104111 32339769
62. Mohammed A. Alghetaa H.F.K.F.K. Miranda K. Wilson K. Singh N.P.P. Cai G. Putluri N. Nagarkatti P. Nagarkatti M. Î”9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression Int. J. Mol. Sci. 2020 21 6244 10.3390/ijms21176244 32872332
63. Kusher D.I. Dawson L.O. Taylor A.C. Djeu J.Y. Effect of the Psychoactive Metabolite of Marijuana, Î”9-Tetrahydrocannabinol (THC), on the Synthesis of Tumor Necrosis Factor by Human Large Granular Lymphocytes Cell. Immunol. 1994 154 99 108 10.1006/cimm.1994.1060 8118892
64. Newton C.A. Klein T.W. Friedman H. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection Infect. Immun. 1994 62 4015 4020 10.1128/IAI.62.9.4015-4020.1994 8063421
65. SanGiovanni E. Fumagalli M. Pacchetti B. Piazza S. Magnavacca A. Khalilpour S. Melzi G. Martinelli G. Dellâ€™Agli M. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury Phytother. Res. 2019 33 2083 2093 10.1002/ptr.6400 31250491
66. Casey S.L. Atwal N. Vaughan C.W. Cannabis constituent synergy in a mouse neuropathic pain model Pain 2017 158 2452 2460 10.1097/j.pain.0000000000001051 28885457
67. Granja A.G. Carrillo-Salinas F. Pagani A. GÃ³mez-CaÃ±as M. Negri R. Navarrete C. Mecha M. Mestre L. Fiebich B.L. Cantarero I. A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis J. Neuroimmune Pharmacol. 2012 7 1002 1016 10.1007/s11481-012-9399-3 22971837
68. Shebaby W. Saliba J. Faour W.H. Ismail J. El Hage M. Daher C.F. Taleb R.I. Nehmeh B. Dagher C. Chrabieh E. In vivo and in vitro anti-inflammatory activity evaluation of Lebanese Cannabis sativa L. ssp. indica (Lam.) J. Ethnopharmacol. 2021 270 113743 10.1016/j.jep.2020.113743 33359187
69. Downer E.J. Anti-inflammatory Potential of Terpenes Present in Cannabis sativa L. ACS Chem. Neurosci. 2020 11 659 662 10.1021/acschemneuro.0c00075 32091871
70. Ligresti A. Moriello A.S. Starowicz K. Matias I. Pisanti S. De Petrocellis L. Laezza C. Portella G. Bifulco M. Di Marzo V. Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma J. Pharmacol. Exp. Ther. 2006 318 1375 1387 10.1124/jpet.106.105247 16728591
71. Romano B. Borrelli F. Pagano E. Cascio M.G. Pertwee R.G. Izzo A.A. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol Phytomedicine 2014 21 631 639 10.1016/j.phymed.2013.11.006 24373545
72. Li J. Liu C. Sato T. Novel Antitumor Invasive Actions of p-Cymene by Decreasing MMP-9/TIMP-1 Expression Ratio in Human Fibrosarcoma HT-1080 Cells Biol. Pharm. Bull. 2016 39 1247 1253 10.1248/bpb.b15-00827 27476935
73. Andre C.M. Hausman J.-F. Guerriero G. Cannabis sativa: The Plant of the Thousand and One Molecules Front. Plant. Sci. 2016 7 19 10.3389/fpls.2016.00019 26870049
74. Amorim B.O. Hamani C. Ferreira E. Miranda M.F. Fernandes M.J.S. Rodrigues A.M. De Almeida A.-C.G. Covolan L. Effects of A1 receptor agonist/antagonist on spontaneous seizures in pilocarpine-induced epileptic rats Epilepsy Behav. 2016 61 168 173 10.1016/j.yebeh.2016.05.036 27371881
75. Ashton J.C. Glass J.C.A.A.M. The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration Curr. Neuropharmacol. 2007 5 73 80 10.2174/157015907780866884 18615177
76. Noonan J. Tanveer R. Klompas A. Gowran A. McKiernan J. Campbell V.A. Endocannabinoids Prevent Î²-Amyloid-mediated Lysosomal Destabilization in Cultured Neurons J. Biol. Chem. 2010 285 38543 38554 10.1074/jbc.M110.162040 20923768
77. Maresz K. Pryce G. Ponomarev E.D. Marsicano G. Croxford J.L. Shriver L.P. Ledent C. Cheng X. Carrier E.J. Mann M.K. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells Nat. Med. 2007 13 492 497 10.1038/nm1561 17401376
78. Rajesh M. Mukhopadhyay P. BÃ¡tkai S. HaskÃ³ G. Liaudet L. Huffman J.W. Csiszar A. Ungvari Z. Mackie K. Chatterjee S. CB2-receptor stimulation attenuates TNF-Î±-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion Am. J. Physiol. Circ. Physiol. 2007 293 H2210 H2218 10.1152/ajpheart.00688.2007
79. Majdi F. Taheri F. Salehi P. Motaghinejad M. Safari S. Cannabinoids Î”9-tetrahydrocannabinol and cannabidiol may be effective against methamphetamine induced mitochondrial dysfunction and inflammation by modulation of Toll-like type-4(Toll-like 4) receptors and NF-ÎºB signaling Med. Hypotheses 2019 133 109371 10.1016/j.mehy.2019.109371 31465975
80. Hunter S.A. Burstein S.H. Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis Life Sci. 1997 60 1563 1573 10.1016/S0024-3205(97)00122-7 9126878
81. Henriquez J.E. Bach A.P. Matos-Fernandez K.M. Crawford R.B. Kaminski N.E. Î”9-Tetrahydrocannabinol (THC) Impairs CD8+ T Cell-Mediated Activation of Astrocytes J. Neuroimmune Pharmacol. 2020 15 863 874 10.1007/s11481-020-09912-z 32215844
82. Al-Ghezi Z.Z. Miranda K. Nagarkatti M. Nagarkatti P.S. Combination of Cannabinoids, Î”9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways Front. Immunol. 2019 10 1921 10.3389/fimmu.2019.01921 31497013
83. Ramer R. Schwarz R. Hinz B. Modulation of the Endocannabinoid System as a Potential Anticancer Strategy Front. Pharmacol. 2019 10 430 10.3389/fphar.2019.00430 31143113
84. Cianchi F. Papucci L. Schiavone N. Lulli M. Magnelli L. Vinci M.C. Messerini L. Manera C. Ronconi E. Romagnani P. Cannabinoid Receptor Activation Induces Apoptosis through Tumor Necrosis Factor Î±â€“Mediated Ceramide De novo Synthesis in Colon Cancer Cells Clin. Cancer Res. 2008 14 7691 7700 10.1158/1078-0432.CCR-08-0799 19047095
85. Galve-Roperh I. SÃ¡nchez C. CortÃ©s M.L. Del Pulgar T.G. Izquierdo M. GuzmÃ¡n M. Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation Nat. Med. 2000 6 313 319 10.1038/73171 10700234
86. Anis O. Vinayaka A. Shalev N. Namdar D. Nadarajan S. Anil S. Cohen O. Belausov E. Ramon J. Gati E.M. Cannabis-Derived Compounds Cannabichromene and Î”9-Tetrahydrocannabinol Interact and Exhibit Cytotoxic Activity against Urothelial Cell Carcinoma Correlated with Inhibition of Cell Migration and Cytoskeleton Organization Molecules 2021 26 465 10.3390/molecules26020465 33477303
87. Kazemi F. Karimi I. Yousofvand N. Molecular docking study of lignanamides from Cannabis sativa against P-glycoprotein Silico Pharmacol. 2021 9 6 10.1007/s40203-020-00066-7 33442533
88. Suttorp M. BornhÃ¤user M. Metzler M. Millot F. Schleyer E. Pharmacology and pharmacokinetics of imatinib in pediatric patients Expert Rev. Clin. Pharmacol. 2017 11 219 231 10.1080/17512433.2018.1398644 29076384
89. MolnÃ¡r J. SzabÃ³ D. Pusztai R. Mucsi I. Berek L. Ocsovszki I. Kawata E. Shoyama Y. Membrane associated antitumor effects of crocine-, ginsenoside- and cannabinoid derivates Anticancer Res. 2000 20 861 867 10810367
90. Yan X. Tang J. Passos C.D.S. Nurisso A. SimÃµes-Pires C.A. Ji M. Lou H. Fan P. Characterization of Lignanamides from Hemp (Cannabis sativa L.) Seed and Their Antioxidant and Acetylcholinesterase Inhibitory Activities J. Agric. Food Chem. 2015 63 10611 10619 10.1021/acs.jafc.5b05282 26585089
91. Deng L. Ng L. Ozawa T. Stella N. Quantitative Analyses of Synergistic Responses between Cannabidiol and DNA-Damaging Agents on the Proliferation and Viability of Glioblastoma and Neural Progenitor Cells in Culture J. Pharmacol. Exp. Ther. 2017 360 215 224 10.1124/jpet.116.236968 27821713
92. Shah V. Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches Recent Patents Anti-Cancer Drug Discov. 2018 13 70 85 10.2174/1574892812666171129142023 29189177
93. Singer E. Judkins J.C. Salomonis N. Matlaf L. Soteropoulos P. McAllister S.D. Soroceanu L. Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma Cell Death Dis. 2015 6 e1601 10.1038/cddis.2014.566 25590811
94. Alharris E. Singh N.P. Nagarkatti P.S. Nagarkatti M. Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells Oncotarget 2019 10 45 59 10.18632/oncotarget.26534 30713602
95. Kosgodage U.S. Uysal-Onganer P. MacLatchy A. Mould R. Nunn A.V. Guy G.W. Kraev I. Chatterton N.P. Thomas E.L. Inal J.M. Cannabidiol Affects Extracellular Vesicle Release, miR21 and miR126, and Reduces Prohibitin Protein in Glioblastoma Multiforme Cells Transl. Oncol. 2019 12 513 522 10.1016/j.tranon.2018.12.004 30597288
96. Carracedo A. Gironella M. Lorente M. Garcia S. GuzmÃ¡n M. Velasco G. Iovanna J.L. Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stressâ€“Related Genes Cancer Res. 2006 66 6748 6755 10.1158/0008-5472.CAN-06-0169 16818650
97. Mc Allister S.D. Chan C. Taft R.J. Luu T. Abood M.E. Moore D.H. Aldape K. Yount G. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells J. Neuro-Oncol. 2005 74 31 40 10.1007/s11060-004-5950-2
98. BlÃ¡zquez C. Salazar M. Carracedo A. Lorente M. Egia A. GonzÃ¡lez-Feria L. Haro A. Velasco G. GuzmÃ¡n M. Cannabinoids Inhibit Glioma Cell Invasion by Down-regulating Matrix Metalloproteinase-2 Expression Cancer Res. 2008 68 1945 1952 10.1158/0008-5472.CAN-07-5176 18339876
99. GuzmÃ¡n M. Duarte M.J. BlÃ¡zquez C. Ravina J. Rosa M.C. Galve-Roperh I. SÃ¡nchez C. Velasco G. GonzÃ¡lez-Feria L. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme Br. J. Cancer 2006 95 197 203 10.1038/sj.bjc.6603236 16804518
100. HernÃ¡ndez-Tiedra S. FabriÃ s G. DÃ¡vila D. Salanueva Ã.J. Casas J. Montes L.R. AntÃ³n Z. GarcÃ­a-Taboada E. Salazar-Roa M. Lorente M. Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization Autophagy 2016 12 2213 2229 10.1080/15548627.2016.1213927 27635674
101. Marcu J.P. Christian R.T. Lau D. Zielinski A.J. Horowitz M.P. Lee J. Pakdel A. Allison J. Limbad C. Moore D.H. Cannabidiol Enhances the Inhibitory Effects of Î”9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival Mol. Cancer Ther. 2010 9 180 189 10.1158/1535-7163.MCT-09-0407 20053780
102. Baram L. Peled E. Berman P. Yellin B. Besser E. Benami M. Louria-Hayon I. Lewitus G.M. Meiri D. The heterogeneity and complexity of Cannabis extracts as antitumor agents Oncotarget 2019 10 4091 4106 10.18632/oncotarget.26983 31289609
103. LÃ³pez-Valero I. Saiz-Ladera C. Torres S. HernÃ¡ndez-Tiedra S. GarcÃ­a-Taboada E. RodrÃ­guez-FornÃ©s F. Barba M. DÃ¡vila D. Salvador-Tormo N. GuzmÃ¡n M. Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide Biochem. Pharmacol. 2018 157 266 274 10.1016/j.bcp.2018.09.007 30195736
104. Ivanov V.N. Wu J. Hei T.K. Regulation of human glioblastoma cell death by combined treatment of cannabidiol, Î³-radiation and small molecule inhibitors of cell signaling pathways Oncotarget 2017 8 74068 74095 10.18632/oncotarget.18240 29088769
105. Ivanov V.N. Wu J. Wang T.J.C. Hei T.K. Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and Î³-irradiation in human glioblastoma cells Oncotarget 2019 10 825 846 10.18632/oncotarget.26582 30783513
106. Massi P. Vaccani A. Ceruti S. Colombo A. Abbracchio M.P. Parolaro D. Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines J. Pharmacol. Exp. Ther. 2003 308 838 845 10.1124/jpet.103.061002 14617682
107. Massi P. Vaccani A. Bianchessi S. Costa B. Macchi P. Parolaro D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells Cell. Mol. Life Sci. 2006 63 2057 2066 10.1007/s00018-006-6156-x 16909207
108. Milian L. Mata M. Alcacer J. Oliver M. Sancho-Tello M. De Llano J.J.M. Camps C. Galbis J. Carretero J. Carda C. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro PLoS ONE 2020 15 e0228909 10.1371/journal.pone.0228909 32049991
109. Ramer R. Rohde A. Merkord J. Rohde H. Hinz B. Decrease of Plasminogen Activator Inhibitor-1 May Contribute to the Anti-Invasive Action of Cannabidiol on Human Lung Cancer Cells Pharm. Res. 2010 27 2162 2174 10.1007/s11095-010-0219-2 20668920
110. Ramer R. Heinemann K. Merkord J. Rohde H. Salamon A. Linnebacher M. Hinz B. COX-2 and PPAR-Î³ Confer Cannabidiol-Induced Apoptosis of Human Lung Cancer Cells Mol. Cancer Ther. 2013 12 69 82 10.1158/1535-7163.MCT-12-0335 23220503
111. Chen C. Shenoy A.K. Padia R. Fang D. Jing Q. Yang P. Su S.-B. Huang S. Suppression of lung cancer progression by isoliquiritigenin through its metabolite 2, 4, 2â€™, 4â€™-Tetrahydroxychalcone J. Exp. Clin. Cancer Res. 2018 37 243 10.1186/s13046-018-0902-4 30285892
112. Hosami F. Manayi A. Salimi V. Khodakhah F. Nourbakhsh M. Nakstad B. Tavakoli-Yaraki M. The pro-apoptosis effects of Echinacea purpurea and Cannabis sativa extracts in human lung cancer cells through caspase-dependent pathway BMC Complement. Med. Ther. 2021 21 1 12 10.1186/s12906-021-03204-6 33386071
113. Alexander A. Smith P.F. Rosengren R.J. Cannabinoids in the treatment of cancer Cancer Lett. 2009 285 6 12 10.1016/j.canlet.2009.04.005 19442435
114. Haustein M. Ramer R. Linnebacher M. Manda K. Hinz B. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1 Biochem. Pharmacol. 2014 92 312 325 10.1016/j.bcp.2014.07.014 25069049
115. Elbaz M. Nasser M.W. Ravi J. Wani N.A. Ahirwar D.K. Zhao H. Oghumu S. Satoskar A.R. Shilo K. Carson W.E. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer Mol. Oncol. 2015 9 906 919 10.1016/j.molonc.2014.12.010 25660577
116. Sultan A.S. Marie M.A. Sheweita S.A. Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines Breast 2018 41 34 41 10.1016/j.breast.2018.06.009 30007266
117. Ward S.J. McAllister S.D. Kawamura R. Murase R. Neelakantan H. Walker E.A. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5- HT 1A receptors without diminishing nervous system function or chemotherapy efficacy Br. J. Pharmacol. 2014 171 636 645 10.1111/bph.12439 24117398
118. McAllister S.D. Glass M. CB(1) and CB(2) receptor-mediated signalling: A focus on endocannabinoids Prostaglandins Leukot. Essent. Fatty Acids 2002 66 161 171 10.1054/plef.2001.0344 12052033
119. Shrivastava A. Kuzontkoski P.M. Groopman J.E. Prasad A. Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy Mol. Cancer Ther. 2011 10 1161 1172 10.1158/1535-7163.MCT-10-1100 21566064
120. Leo A. Russo E. Elia M. Cannabidiol and epilepsy: Rationale and therapeutic potential Pharmacol. Res. 2016 107 85 92 10.1016/j.phrs.2016.03.005 26976797
121. McAllister S.D. Soroceanu L. Desprez P.-Y. The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids J. Neuroimmune Pharmacol. 2015 10 255 267 10.1007/s11481-015-9608-y 25916739
122. Blasco-Benito S. Seijo-Vila M. Caro-Villalobos M. Tundidor I. Andradas C. GarcÃ­a-Taboada E. Wade J. Smith S. GuzmÃ¡n M. PÃ©rez-GÃ³mez E. Appraising the â€œentourage effectâ€: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer Biochem. Pharmacol. 2018 157 285 293 10.1016/j.bcp.2018.06.025 29940172
123. Emery S.M. Alotaibi M.R. Tao Q. Selley D.E. Lichtman A.H. Gewirtz D.A. Combined Antiproliferative Effects of the Aminoalkylindole WIN55,212-2 and Radiation in Breast Cancer Cells J. Pharmacol. Exp. Ther. 2014 348 293 302 10.1124/jpet.113.205120 24259678
124. Qamri Z. Preet A. Nasser M.W. Bass C.E. Leone G. Barsky S.H. Ganju R.K. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer Mol. Cancer Ther. 2009 8 3117 3129 10.1158/1535-7163.MCT-09-0448 19887554
125. Nasser M.W. Qamri Z. Deol Y.S. Smith D. Shilo K. Zou X. Ganju R.K. Crosstalk between Chemokine Receptor CXCR4 and Cannabinoid Receptor CB2 in Modulating Breast Cancer Growth and Invasion PLoS ONE 2011 6 e23901 10.1371/journal.pone.0023901 21915267
126. Rahman S. Archana A. Dutta D. Kumar V. Kim J. Jan A.T. Minakshi R. The onus of cannabinoids in interrupting the molecular odyssey of breast cancer: A critical perspective on UPRER and beyond Saudi Pharm. J. 2019 27 437 445 10.1016/j.jsps.2019.01.005 30976189
127. McAllister S.D. Christian R.T. Horowitz M.P. Garcia A. Desprez P.-Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells Mol. Cancer Ther. 2007 6 2921 2927 10.1158/1535-7163.MCT-07-0371 18025276
128. Li Y.-L. Yeung C.-M. Chiu L.C.M. Cen Y.-Z. Ooi V.E.C. Chemical composition and antiproliferative activity of essential oil from the leaves of a medicinal herb, Schefflera heptaphylla Phytother. Res. 2009 23 140 142 10.1002/ptr.2567 18814213
129. Haag J.D. Lindstrom M.J. Gould M.N. Limonene-induced regression of mammary carcinomas Cancer Res. 1992 52 4021 4026 1617679
130. Gould M.N. Moore C.J. Zhang R. Wang B. Kennan W.S. Haag J.D. Limonene chemoprevention of mammary carcinoma induction following direct in situ transfer of v-Ha-ras Cancer Res. 1994 54 3540 3543 8012978
131. Elegbede J.A. Elson C.E. Qureshi A. Tanner M.A. Gould M.N. Regression of Rat Primary Mammary Tumors Following Dietary d-Limonene2 J. Natl. Cancer Inst. 1986 76 323 325 10.1093/jnci/76.2.323 3080636
132. Aviello G. Romano B. Borrelli F. Capasso R. Gallo L. Piscitelli F. Di Marzo V. Izzo A.A. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer J. Mol. Med. 2012 90 925 934 10.1007/s00109-011-0856-x 22231745
133. Wright K. Rooney N. Feeney M. Tate J. Robertson D. Welham M. Ward S. Differential Expression of Cannabinoid Receptors in the Human Colon: Cannabinoids Promote Epithelial Wound Healing Gastroenterology 2005 129 437 453 10.1016/j.gastro.2005.05.026 16083701
134. Jeong S. Yun H.K. Jeong Y.A. Jo M.J. Kang S.H. Kim J.L. Kim D.Y. Park S.H. Kim B.R. Na Y.J. Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells Cancer Lett. 2019 447 12 23 10.1016/j.canlet.2019.01.011 30660647
135. Jeong S. Kim B.G. Kim D.Y. Kim B.R. Kim J.L. Park S.H. Na Y.J. Jo M.J. Yun H.K. Jeong Y.A. Cannabidiol Overcomes Oxaliplatin Resistance by Enhancing NOS3- and SOD2-Induced Autophagy in Human Colorectal Cancer Cells Cancers 2019 11 781 10.3390/cancers11060781 31195721
136. Alhamoruni A. Lee A.C. Wright K.L. Larvin M. Oâ€™Sullivan S.E. Pharmacological Effects of Cannabinoids on the Caco-2 Cell Culture Model of Intestinal Permeability J. Pharmacol. Exp. Ther. 2010 335 92 102 10.1124/jpet.110.168237 20592049
137. Alhamoruni A. Wright K. Larvin M. Oâ€™Sullivan S.E. Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability Br. J. Pharmacol. 2012 165 2598 2610 10.1111/j.1476-5381.2011.01589.x 21745190
138. Watzl B. Scuderi P. Watson R.R. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro Int. J. Immunopharmacol. 1991 13 1091 1097 10.1016/0192-0561(91)90160-9 1667651
139. Petrosino S. Verde R. Vaia M. AllarÃ  M. Iuvone T. Di Marzo V. Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis J. Pharmacol. Exp. Ther. 2018 365 652 663 10.1124/jpet.117.244368 29632236
140. Lah T. Novak M. Almidon M.P. Marinelli O. BaÅ¡koviÄ B.Å½. Majc B. Mlinar M. BoÅ¡njak R. Breznik B. Zomer R. Cannabigerol Is a Potential Therapeutic Agent in a Novel Combined Therapy for Glioblastoma Cells 2021 10 340 10.3390/cells10020340 33562819
141. Borrelli F. Pagano E. Romano B. Panzera S. Maiello F. Coppola D. De Petrocellis L. Buono L. Orlando P. Izzo A.A. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid Carcinogenesis 2014 35 2787 2797 10.1093/carcin/bgu205 25269802
142. Sobral M.V. Xavier A.L. Lima T.C. De Sousa D.P. Antitumor Activity of Monoterpenes Found in Essential Oils Sci. World J. 2014 2014 1 35 10.1155/2014/953451 25401162
143. Ferraz R.P. Bomfim D.S. Carvalho N.C. Soares M.B. da Silva T.B. Machado W.J. Prata A.P.N. Costa E.V. Moraes V.R.S. Nogueira P.C.L. Cytotoxic effect of leaf essential oil of Lippia gracilis Schauer (Verbenaceae) Phytomedicine 2013 20 615 621 10.1016/j.phymed.2013.01.015 23453306
144. Da Silva S.L. Figueiredo P.M. Yano T. Cytotoxic evaluation of essential oil from Zanthoxylum rhoifolium Lam. leaves Acta Amaz. 2007 37 281 286 10.1590/S0044-59672007000200015
145. Jia S.-S. Xi G.-P. Zhang M. Chen Y.-B. Lei B. Dong X.-S. Yang Y.-M. Induction of apoptosis by D-limonene is mediated by inactivation of Akt in LS174T human colon cancer cells Oncol. Rep. 2012 29 349 354 10.3892/or.2012.2093 23117412
146. Arboleda M.F. Prosk E. Cyr C. Gamaoun R. Vigano A. Medical cannabis in supportive cancer care: Lessons from Canada Support. Care Cancer 2020 28 2999 3001 10.1007/s00520-020-05403-2 32172409
147. Zolotov Y. Vulfsons S. Zarhin D. Sznitman S. Medical cannabis: An oxymoron? Physiciansâ€™ perceptions of medical cannabis Int. J. Drug Policy 2018 57 4 10 10.1016/j.drugpo.2018.03.025 29653439
148. Cyr C. Arboleda M.F. Aggarwal S.K. Balneaves L.G. Daeninck P. NÃ©ron A. Prosk E. Vigano A. Cannabis in palliative care: Current challenges and practical recommendations Ann. Palliat. Med. 2018 7 463 477 10.21037/apm.2018.06.04 30180728
149. Pauli C.S. Conroy M. Heuvel B.D.V. Park S.-H. Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects Front. Pharmacol. 2020 11 63 10.3389/fphar.2020.00063 32161538
150. Iffland K. Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies Cannabis Cannabinoid Res. 2017 2 139 154 10.1089/can.2016.0034 28861514
151. Bar-Sela G. Zalman D. Semenysty V. Ballan E. The Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients: Pilot Study Integr. Cancer Ther. 2019 18 1534735419881498 10.1177/1534735419881498 31595793
152. Strasser F. LÃ¼ftner D. Possinger K. Ernst G. Ruhstaller T. Meissner W. Ko Y.-D. Schnelle M. Reif M. Cerny T. Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group J. Clin. Oncol. 2006 24 3394 3400 10.1200/jco.2005.05.1847 16849753
153. Abu-Amna M. Salti T. Khoury M. Cohen I. Bar-Sela G. Medical Cannabis in Oncology: A Valuable Unappreciated Remedy or an Undesirable Risk? Curr. Treat. Options Oncol. 2021 22 1 18 10.1007/s11864-020-00811-2 33439370
154. Kenyon J. Liu W. Dalgleish A. Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol Anticancer Res. 2018 38 5831 5835 10.21873/anticanres.12924 30275207
155. National Academies of Sciences, Engineering, and Medicine Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research National Academies Press (US) Cambridge, MA, USA 2017
156. Whiting P.F. Wolff R.F. Deshpande S. Di Nisio M. Duffy S. Hernandez A.V. Keurentjes J.C. Lang S. Misso K. Ryder S. Cannabinoids for Medical Use JAMA 2015 313 2456 2473 10.1001/jama.2015.6358 26103030
157. MÃ¼cke M. Phillips T. Radbruch L. Petzke F. HÃ¤user W. Cannabis-based medicines for chronic neuropathic pain in adults Cochrane Database Syst. Rev. 2018 3 CD012182 10.1002/14651858.CD012182.pub2 29513392
158. Hill K.P. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems JAMA 2015 313 2474 2483 10.1001/jama.2015.6199 26103031
159. Nugent S.M. Morasco B.J. Oâ€™Neil M.E. Freeman M. Low A. Kondo K. Elven C. Zakher B. Motuâ€™Apuaka M. Paynter R. The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms Ann. Intern. Med. 2017 167 319 331 10.7326/M17-0155 28806817
160. Darkovska-Serafimovska M. Serafimovska T. Arsova-Sarafinovska Z. Stefanoski S. Keskovski Z. Balkanov T. Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases J. Pain Res. 2018 11 837 842 10.2147/JPR.S160556 29719417
161. Meng H. Dai T. Hanlon J.G. Downar J. Alibhai S.M. Clarke H. Cannabis and cannabinoids in cancer pain management Curr. Opin. Support. Palliat. Care 2020 14 87 93 10.1097/SPC.0000000000000493 32332209
162. Levy C. Galenbeck E. Magid K. Cannabis for Symptom Management in Older Adults Med. Clin. N. Am. 2020 104 471 489 10.1016/j.mcna.2020.01.004 32312410
163. Lossignol D. Cannabinoids: A new approach for pain control? Curr. Opin. Oncol. 2019 31 275 279 10.1097/CCO.0000000000000523 30789867
164. Noyes R. Brunk S.F. Baram D.A. Canter A. Analgesic Effect of Delta-9-Tetrahydrocannabinol J. Clin. Pharmacol. 1975 15 139 143 10.1002/j.1552-4604.1975.tb02348.x 1091664
165. Noyes R. Brunk S.F. Avery D.H. Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine Clin. Pharmacol. Ther. 1975 18 84 89 10.1002/cpt197518184 50159
166. Johnson J.R. Burnell-Nugent M. Lossignol D. Ganae-Motan E.D. Potts R. Fallon M.T. Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain J. Pain Symptom Manag. 2010 39 167 179 10.1016/j.jpainsymman.2009.06.008 19896326
167. Portenoy R.K. Ganae-Motan E.D. Allende S. Yanagihara R. Shaiova L. Weinstein S. McQuade R. Wright S. Fallon M.T. Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial J. Pain 2012 13 438 449 10.1016/j.jpain.2012.01.003 22483680
168. Staquet M. Gantt C. Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain Clin. Pharmacol. Ther. 1978 23 397 401 10.1002/cpt1978234397 343969
169. Jochimsen P.R. Lawton R.L. Versteeg K. Noyes R. Effect of benzopyranoperidine, a Î”-9-THC congener, on pain Clin. Pharmacol. Ther. 1978 24 223 227 10.1002/cpt1978242223 354840
170. Johnson J.R. Lossignol D. Burnell-Nugent M. Fallon M.T. An Open-Label Extension Study to Investigate the Long-Term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal THC Spray in Patients With Terminal Cancer-Related Pain Refractory to Strong Opioid Analgesics J. Pain Symptom Manag. 2013 46 207 218 10.1016/j.jpainsymman.2012.07.014
171. Van Sickle M.D. Oland L.D. Ho W. Hillard C.J. Mackie K. Davison J.S. Sharkey K.A. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret Gastroenterology 2001 121 767 774 10.1053/gast.2001.28466 11606489
172. Turgeman I. Bar-Sela G. Cannabis Use in Palliative Oncology: A Review of the Evidence for Popular Indications Isr. Med. Assoc. J. IMAJ 2017 19 85 88 28457056
173. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential J. Ethnopharmacol. 2006 105 1 25 10.1016/j.jep.2006.02.001 16540272
174. Duran M. PÃ©rez E. Abanades S. Vidal X. Saura C. Majem M. Arriola E. Rabanal M. Pastor A. FarrÃ© M. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting Br. J. Clin. Pharmacol. 2010 70 656 663 10.1111/j.1365-2125.2010.03743.x 21039759
175. Sallan S.E. Zinberg N.E. Frei E. Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy N. Engl. J. Med. 1975 293 795 797 10.1056/NEJM197510162931603 1099449
176. Brisbois T.D. de Kock I.H. Watanabe S.M. Mirhosseini M. Lamoureux D.C. Chasen M. MacDonald N. Baracos V.E. Wismer W.V. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: Results of a randomized, double-blind, placebo-controlled pilot trial Ann. Oncol. 2011 22 2086 2093 10.1093/annonc/mdq727 21343383

